INT57088

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.19
First Reported 1993
Last Reported 2009
Negated 1
Speculated 0
Reported most in Abstract
Documents 9
Total Number 9
Disease Relevance 2.27
Pain Relevance 2.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (Slc14a2) plasma membrane (Slc14a2)
Anatomy Link Frequency
sympathetic 1
ear 1
Slc14a2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
opioid receptor 5 100.00 Very High Very High Very High
Antinociceptive 8 99.98 Very High Very High Very High
narcan 3 97.96 Very High Very High Very High
antagonist 1 97.76 Very High Very High Very High
tetrodotoxin 7 96.64 Very High Very High Very High
Morphine 9 96.32 Very High Very High Very High
adenocard 10 88.52 High High
anesthesia 2 87.28 High High
lidocaine 2 80.48 Quite High
antinociception 4 75.00 Quite High
Disease Link Frequency Relevance Heat
Hypoxia 15 96.36 Very High Very High Very High
Ocular Hypertension 8 92.64 High High
Miosis 4 85.04 High High
Ganglion Cysts 8 83.44 Quite High
Edema 2 80.84 Quite High
Endolymphatic Hydrops 4 75.60 Quite High
Increased Venous Pressure Under Development 2 75.60 Quite High
Hyperalgesia 3 73.68 Quite High
Hypertension 1 70.96 Quite High
Cardiovascular Disorder Under Development 1 50.00 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Before beginning of autoregulatory tests two groups of animals were treated with nitric oxide synthase inhibitor L-NAME.
Negative_regulation (inhibitor) of L-NAME
1) Confidence 0.19 Published 2009 Journal Georgian Med News Section Abstract Doc Link 19202232 Disease Relevance 0.07 Pain Relevance 0.09
The inhibitors of L-arginine-NO synthase L-NG-nitro arginine methyl-ester (L-NAME) and L-NOARG (L-NG-nitro arginine) reduced the NANC relaxations elicited by EFS in a dose- and time-dependent manner; L-NOARG was two times more potent than L-NAME (IC50 = 14.3 vs 25.2 microM) and these effects were partially reverted by the addition of 300-1000 microM L-arginine but not of 300-1000 microMD-arginine.
Negative_regulation (inhibitors) of L-NAME
2) Confidence 0.13 Published 1993 Journal Braz. J. Med. Biol. Res. Section Abstract Doc Link 8136734 Disease Relevance 0 Pain Relevance 0
The lightly anesthetized (0.5% halothane, 70% nitrous oxide) and paralyzed (doxacurium) animals were given N omega-nitro-L-arginine methyl ester (L-NAME), a NO synthase inhibitor, 2 mg/kg/min (n = 6) or saline (n = 5) intravenously for 30 minutes.
Neg (NO) Negative_regulation (inhibitor) of L-NAME
3) Confidence 0.08 Published 1996 Journal Reg Anesth Section Body Doc Link 8744668 Disease Relevance 0 Pain Relevance 0
In the first, we tested the effects of NOS inhibition, via topical L-NAME (1 mM), on moderate (PaO2 approximately 46 mmHg) then severe (PaO2 approximately 34 mmHg) hypoxia-induced dilation.
Negative_regulation (inhibition) of L-NAME associated with hypoxia
4) Confidence 0.06 Published 1995 Journal Brain Res. Section Abstract Doc Link 8750962 Disease Relevance 0.46 Pain Relevance 0.45
It can be suggested that L-NAME causes the antinociceptive effect by stimulation of the arginine/ NO/ cGMP pathway, since the antinociceptive effect of L-NAME can be antagonized by L-NMMA and abolished by the guanylate cyclase inhibitors (MB and ODQ).
Negative_regulation (effect) of L-NAME associated with antinociceptive
5) Confidence 0.05 Published 2000 Journal Mediators Inflamm Section Abstract Doc Link PMC1781740 Disease Relevance 0.20 Pain Relevance 0.75
Using the cardiac dialysis technique in the anesthetized cat, we examined the effects of NG-nitro-L-arginine methyl ester (L-NAME, a nitric oxide (NO) synthase inhibitor, 100 mM) on sympathetic modulation.
Negative_regulation (inhibitor) of L-NAME in sympathetic
6) Confidence 0.02 Published 2003 Journal Neurosci. Lett. Section Abstract Doc Link 14665417 Disease Relevance 0 Pain Relevance 0
Morphine-induced ocular effects were challenged by a pre-treatment with the non-selective opioid receptor antagonist, naloxone (100 microg/30 microl), the nitric oxide synthase inhibitor, N(omega)-nitro-L-arginine methyl ester (L-NAME, 1%, 30 microl), or the non-selective mu3 opioid receptor inhibitor, reduced L-glutathione (GSH, 1%, 30 microl).
Negative_regulation (inhibitor) of L-NAME associated with antagonist, narcan, opioid receptor and morphine
7) Confidence 0.00 Published 2006 Journal Eur. J. Pharmacol. Section Abstract Doc Link 16516192 Disease Relevance 0.81 Pain Relevance 0.95
NG-nitro-L-arginine methyl ester (L-NAME), a competitive inhibitor of nitric oxide synthase, was infused intravenously to assess basal nitric oxide (an endogenous vasodilator) production in the hydropic ear.
Negative_regulation (inhibitor) of L-NAME in ear
8) Confidence 0.00 Published 1995 Journal Hear. Res. Section Abstract Doc Link 8600117 Disease Relevance 0.35 Pain Relevance 0.07
With infusion of L-NAME, CBF was reduced by 9.16 +/- 11%, 10.7 +/- 10% (P = 0.87), and 16.6 +/- 18% (P = 0.95), in the control, 6-week, and 12-week animals, respectively.
Negative_regulation (reduced) of L-NAME
9) Confidence 0.00 Published 1995 Journal Hear. Res. Section Abstract Doc Link 8600117 Disease Relevance 0.38 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox